Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

Reporting from 2021 ASCO Annual Meeting, Ian Chau reports on practice changing results of immunotherapy in gastric and oesophageal cancers. He comments first on CheckMate 648 testing nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy in advanced oesophageal squamous cell carcinoma, then on CheckMate 649 evaluating the benefits of adding nivolumab to first-line chemotherapy in advanced gastroesophageal cancer. Finally he discusses the efficacy and safety results from CheckMate 577 testing adjuvant nivolumab following neo-adjuvant chemoradiotherapy in resected oesophageal or gastroesophageal junction cancer.

This video was supported with an educational grant from Daiichi Sankyo and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

Produced by the European Society for Medical Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.